Indication
Combination Immunotherapy
2 clinical trials
2 products
Clinical trial
A Single-center, Single-arm, Non-randomized Clinical Study to Evaluate the Efficacy and Safety of Hyperbaric Oxygen Therapy Plus Camrelizumab as a Second-line Treatment in Advanced/Metastatic Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical StudyStatus: Completed, Estimated PCD: 2021-04-01
Product
Lenvatinib + Pembrolizumab